



ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2022 - GENERELL INFORMASJON

Enheten

Organisasjonsnummer: 986 400 990
Organisasjonsform: Aksjeselskap
Foretaksnavn: THERMO FISHER DIAGNOSTICS AS
Forretningsadresse: Ullernchausséen 52
0379 OSLO

Regnskapsår

Årsregnskapets periode: 01.01.2022 - 31.12.2022

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Petrus Thomas Adrianus Van Der Zande

Dato for fastsettelse av årsregnskapet: 07.05.2023

Grunnlag for avgivelse

År 2022: Årsregnskapet er elektronisk innlevert
År 2021: Tall er hentet fra elektronisk innlevert årsregnskap fra 2022

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 05.08.2024



Brønnøysundregistrene

Brønnøysundregistrene Årsregnskap regnskapsåret 2022 for 986400990

Postadresse: 8910 Brønnøysund

Telefoner: Opplysningstelefonen 75 00 75 00 Telefaks 75 00 75 05

E-post: firmapost@brreg.no Internett: www.brreg.no

Organisasjonsnummer: 974 760 673



Resultatregnskap

Beløp i: NOK	Note	2022	2021
RESULTATREGNSKAP			
Inntekter			
Operating revenue	2	123 395 052	130 550 999
Sum inntekter		123 395 052	130 550 999
Kostnader			
Cost of goods sold	3, 4	98 571 109	99 077 323
Staff expenses	5	14 442 853	14 069 010
Depreciation, amortisation and impairment	6	988 554	2 912 075
Other expenses		8 950 266	9 721 944
Sum kostnader		122 952 782	125 780 352
Driftsresultat		442 270	4 770 647
Finansinntekter og finanskostnader			
Annen finansinntekt		995 308	1 215
Sum finansinntekter		995 308	1 215
Annen finanskostnad		1 939 312	777 305
Sum finanskostnader		1 939 312	777 305
Netto finans		-944 004	-776 090
Ordinært resultat før skattekostnad		-501 734	3 994 557
Income tax expense	7	62 414	904 307
Ordinært resultat etter skattekostnad		-564 148	3 090 250
Årsresultat		-564 148	3 090 250
Overføringer og disponeringer			
Overføringer til/fra annen egenkapital		0	3 090 249
Transferred from other equity		-564 148	0
Sum overføringer og disponeringer		-564 148	3 090 249



Balanse

Beløp i: NOK	Note	2022	2021
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Utsatt skattefordel	7	15 929 955	1 160 288
Goodwill	6	0	641 173
Sum immaterielle eiendeler		15 929 955	1 801 461
Varige driftsmidler			
Driftsløsøre, inventar, verktøy, kontormaskiner og lignende	6	1 160 397	1 507 778
Sum varige driftsmidler		1 160 397	1 507 778
Sum anleggsmidler		17 090 352	3 309 239
Omløpsmidler			
Varer			
Current assests: Inventory	4	551 601	760 788
Sum varer		551 601	760 788
Fordringer			
Accounts receivables		12 796 734	12 488 065
Short-term receivables, group companies	8	12 911 841	22 194 814
Other short-term receivables		202 128	204 713
Sum fordringer	9	25 910 703	34 887 592
Bankinnskudd, kontanter og lignende			
Cash and cash equivalents	10	3 722 298	3 660 850
Sum bankinnskudd, kontanter og lignende		3 722 298	3 660 850
Sum omløpsmidler		30 184 602	39 309 230
SUM EIENDELER		47 274 954	42 618 469

BALANSE - EGENKAPITAL OG GJELD

Egenkapital



Balanse

Beløp i: NOK	Note	2022	2021
Innskutt egenkapital			
Share capital (1000 shares a NOK 100)	11	100 000	100 000
Overkurs		200 000	200 000
Sum innskutt egenkapital		300 000	300 000
Opptjent egenkapital			
Retained earnings		22 039 401	7 507 543
Sum opptjent egenkapital		22 039 401	7 507 543
Sum egenkapital	12	22 339 401	7 807 543
Sum langsiktig gjeld		0	0
Kortsiktig gjeld			
Leverandørgjeld		832 360	893 487
Tax payable	7	0	1 172 282
Public duties liabilities		6 798 145	6 117 016
Kortsiktig konserngjeld	8	13 196 163	22 600 800
Other short term liabilities		4 108 885	4 027 342
Sum kortsiktig gjeld		24 935 553	34 810 927
Sum gjeld	9	24 935 553	34 810 927
SUM EGENKAPITAL OG GJELD		47 274 954	42 618 470



Brønnøysundregistrene

ÅRSREGNSKAP FOR REGNSKAPSÅRET 2022 - GENERELL INFORMASJON

Journalnummer: 2023 672037

Enheten

Organisasjonsnummer: 986 400 990
Organisasjonsform: Aksjeselskap
Foretaksnavn: THERMO FISHER DIAGNOSTICS AS
Forretningsadresse: Ullernchausséen 52
0379 OSLO

Regnskapsår

Årsregnskapets periode: 01.01.2022 - 31.12.2022

Konsern

Morselskap i konsern: Nei

Regnskapsregler

Regler for små foretak benyttet: Nei
Benyttet ved utarbeidelsen av
årsregnskapet til selskapet: Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Petrus Thomas Adrianus Van Der Zande
Dato for fastsettelse av årsregnskapet: 07.05.2023

Revisjon

Årsregnskapet er utarbeidet av ekstern
autorisert regnskapsfører: Ja
Ekstern autorisert regnskapsfører har i
løpet av regnskapsåret bistått ved den
løpende regnskapsføringen eller utført
andre tjenester for selskapet enn å
utarbeide årsregnskapet: Ja

Grunnlag for avgivelse

År 2022: Årsregnskap er elektronisk innlevert.
År 2021: Tall er hentet fra elektronisk innlevert årsregnskap fra 2022.

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 12.08.2023

Brønnøysundregistrene
Postadresse: Postboks 900, 8910 Brønnøysund
Telefon: 75 00 75 00
E-post: firmapost@brreg.no Internett: www.brreg.no
Organisasjonsnummer: 974 760 673



Organisasjonsnr: 986 400 990
THERMO FISHER DIAGNOSTICS AS

RESULTATREGNSKAP

Beløp i: NOK	Note	2022	2021
RESULTATREGNSKAP			
Inntekter			
Operating revenue	2	123 395 052	130 550 999
Sum inntekter		123 395 052	130 550 999
Kostnader			
Cost of goods sold	3, 4	98 571 109	99 077 323
Staff expenses	5	14 442 853	14 069 010
Depreciation, amortisation and impairment	6	988 554	2 912 075
Other expenses		8 950 266	9 721 944
Sum kostnader		122 952 782	125 780 352
Driftsresultat		442 270	4 770 647
Finansinntekter og finanskostnader			
Annen finansinntekt		995 308	1 215
Sum finansinntekter		995 308	1 215
Annen finanskostnad		1 939 312	777 305
Sum finanskostnader		1 939 312	777 305
Netto finans		-944 004	-776 090
Ordinært resultat før skattekostnad			
Income tax expense	7	-501 734	3 994 557
		62 414	904 307
Ordinært resultat etter skattekostnad		-564 148	3 090 250
Årsresultat		-564 148	3 090 250
Overføringer og disponeringer			
Overføringer til/fra annen egenkapital		0	3 090 249
Transferred from other equity		-564 148	0
Sum overføringer og disponeringer		-564 148	3 090 249



Organisasjonsnr: 986 400 990
THERMO FISHER DIAGNOSTICS AS

BALANSE

Beløp i: NOK	Note	2022	2021
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Utsatt skattefordel	7	15 929 955	1 160 288
Goodwill	6	0	641 173
Sum immaterielle eiendeler		15 929 955	1 801 461
Varige driftsmidler			
Driftsløsøre, inventar, verktøy, kontormaskiner og lignende	6	1 160 397	1 507 778
Sum varige driftsmidler		1 160 397	1 507 778
Sum anleggsmidler		17 090 352	3 309 239
Omløpsmidler			
Varer			
Current assests: Inventory	4	551 601	760 788
Sum varer		551 601	760 788
Fordringer			
Accounts receivables		12 796 734	12 488 065
Short-term receivables, group companies	8	12 911 841	22 194 814
Other short-term receivables		202 128	204 713
Sum fordringer	9	25 910 703	34 887 592
Bankinnskudd, kontanter og lignende			
Cash and cash equivalents	10	3 722 298	3 660 850
Sum bankinnskudd, kontanter og lignende		3 722 298	3 660 850
Sum omløpsmidler		30 184 602	39 309 230
SUM EIENDELER		47 274 954	42 618 469
BALANSE - EGENKAPITAL OG GJELD			
Egenkapital			
Innskutt egenkapital			
Share capital (1000 shares a NOK 100)	11	100 000	100 000
Overkurs		200 000	200 000
Sum innskutt egenkapital		300 000	300 000



Opptjent egenkapital			
Retained earnings		22 039 401	7 507 543
Sum opptjent egenkapital		22 039 401	7 507 543
Sum egenkapital	12	22 339 401	7 807 543
Sum langsiktig gjeld		0	0
Kortsiktig gjeld			
Leverandørgjeld		832 360	893 487
Tax payable	7	0	1 172 282
Public duties liabilities		6 798 145	6 117 016
Kortsiktig konserngjeld	8	13 196 163	22 600 800
Other short term liabilities		4 108 885	4 027 342
Sum kortsiktig gjeld		24 935 553	34 810 927
Sum gjeld	9	24 935 553	34 810 927
SUM EGENKAPITAL OG GJELD		47 274 954	42 618 470



Organisasjonsnr: 986 400 990
THERMO FISHER DIAGNOSTICS AS

NOTEOPPLYSNINGER - SELSKAP - alle poster oppgitt i hele tall

Note
1

Regnskapsprinsipper

The annual accounts have been prepared in conformity with the provisions of the Accounting Act and good accounting practice.

Note
5

Antall årsverk i regnskapsåret
15.00

<u>Sum</u>	<u>Beløp</u>
<u>Balanseført verdi 31.12.</u>	<u>Varige driftsmidler Immaterielle eiend.</u>

Konsernregnskap

Morselskapet sitt navn

Forretningskontor for morselskapet

Begrunnelse for at datterselskap er utelatt fra konsolideringen

Konsern, tilknyttet selskap m.v. - fordringer og gjeld

Fordringer

<u>Samlet beløp - tilknyttet selskap</u>	<u>Årets</u>	<u>Fjorårets</u>
<u>Samlet beløp - foretak i samme konsern</u>	<u>Årets</u>	<u>Fjorårets</u>
<u>Samlet beløp - foretak i samme konsern</u>	<u>Årets</u>	<u>Fjorårets</u>



Samlet beløp - felles kontrollert virksomhet Årets Fjorårets

Pantstillelse Beløp

Beholdning av egne aksjer Antall Pålydende Andel av aksjek.

Note

5

Lån og sikkerhetsstillelse til medlemmer

Er det gitt lån eller sikkerhetsstillelse til ledende personer: Nei

Opplysninger om:

Medlemmer av:

Mer om lån og sikkerhetsstillelse



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Annual Report 2022

Thermo Fisher Diagnostics AS

Org.no.: 986 400 990



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Thermo Fisher Diagnostics AS

Profit and loss account for the year ended 31 December 2022

	Note	2022	2021
Operating revenue	2	123 395 052	130 550 999
Total revenue		123 395 052	130 550 999
Cost of goods sold	3, 4	98 571 109	99 077 323
Staff expenses	5	14 442 853	14 069 010
Depreciation, amortisation and impairment	6	988 554	2 912 075
Other expenses		8 950 266	9 721 944
Total operating expenses		122 952 782	125 780 353
Operating profit		442 270	4 770 646
Other financial income		995 308	1 215
Other financial expenses		-1 939 312	-777 305
Net financial items		-944 004	-776 090
Profit (loss) before tax		-501 734	3 994 556
Income tax expense	7	62 414	904 307
Profit (loss) after tax		-564 148	3 090 249
Allocation of profit			
Transferred to other equity		0	3 090 249
Transferred from other equity		-564 148	0
Total allocation		-564 148	3 090 249



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Thermo Fisher Diagnostics AS

Balance sheet as of 31 December 2022

	Note	2022	2021
ASSETS			
Non-current assets			
Intangible assets			
Goodwill	6	0	641 173
Deferred tax assets	7	15 929 955	1 160 288
Total intangible assets		15 929 955	1 801 461
Tangible assets			
Fixtures and fittings, tools, office machinery etc.	6	1 160 397	1 507 778
Sum tangible assets		1 160 397	1 507 778
Total non-current assets		17 090 352	3 309 239
Current assets			
Inventory	4	551 601	760 788
Receivables			
Accounts receivables		12 796 734	12 488 065
Short-term receivables, group companies	8	12 911 841	22 194 814
Other short-term receivables		202 128	204 713
Total receivables	9	25 910 704	34 887 592
Cash and cash equivalents	10	3 722 298	3 660 850
Total current assets		30 184 603	39 309 230
TOTAL ASSETS		47 274 955	42 618 469



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBB01C3680

Thermo Fisher Diagnostics AS

Balance sheet as of 31 December 2022

	Note	2022	2021
EQUITY AND LIABILITIES			
EQUITY			
Paid-in capital			
Share capital (1000 shares á NOK 100)	11	100 000	100 000
Share premium reserve		200 000	200 000
Total owners' equity		300 000	300 000
Retained earnings			
Retained earnings		22 039 401	7 507 543
Total retained earnings		22 039 401	7 507 543
Total equity	12	22 339 401	7 807 543
LIABILITIES			
Current liabilities			
Payables to group companies	8	13 196 163	22 600 800
Trade payables		832 360	893 487
Tax payable	7	0	1 172 282
Public duties liabilities		6 798 145	6 117 016
Other short term liabilities		4 108 885	4 027 342
Total current liabilities		24 935 554	34 810 927
Total liabilities	9	24 935 554	34 810 927
TOTAL EQUITY AND LIABILITY		47 274 955	42 618 469

Oslo, 05.07.2023

The board of Thermo Fisher Diagnostics AS

DocuSigned by:

Petrus Thomas Adrianus van der Zande

04449F4F466648D

Petrus Thomas Adrianus Van Der Zande
Chairman of the board

DocuSigned by:

Sara Maria Carrella

87B2E883A4204D

Sara Maria Carrella
Member of the board

DocuSigned by:

Anne Omholt

06083D1C8C534D5

Anne Omholt
Member of the board/General Manager



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Indirect cash flow

Thermo Fisher Diagnostics AS

	2022	2021
Cash flows from operating activities		
Profit/loss before tax	-501 734	3 994 556
Taxation paid	-1 172 282	-672 859
Ordinary depreciation	988 554	2 912 075
Change in inventory	209 186	-132 485
Change in accounts receivable	-308 669	-1 003 022
Change in accounts payable	-183 257	37 572
Change in cash pool	805 910	6 711 486
Change in other current receivables and liabilities	-2 013 931	-9 674 991
Net cash flows from operating activities	-2 176 222	2 172 331
Cash flows from investment activities		
Net acquired cash through acquisition	2 237 670	0
Net cash flows from investment activities	2 237 670	0
Cash flows from financing activities		
Net cash flows from financing activities	0	0
Net change in cash and cash equivalents	61 448	2 172 331
Cash and cash equivalents at the start of the period	3 660 850	1 488 519
Cash and cash equivalents at the end of the period	3 722 298	3 660 850
Cash and cash equivalents consist of:		
Bank deposits	3 722 298	3 660 850



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Accounting principles

The annual accounts have been prepared in conformity with the provisions of the Accounting Act and good accounting practice.

Use of estimates

In the preparation of the annual accounts estimates and assumptions have been made that have affected the profit and loss account and the valuation of assets and liabilities, and uncertain assets and liabilities on the balance sheet date in accordance with generally accepted accounting practice. Areas which to a large extent contain such subjective evaluations, a high degree of complexity, or areas where the assumptions and estimates are material for the annual accounts, are described in the notes.

Foreign currency

Foreign currency transactions are translated at the exchange rate on the date of the transaction. Monetary foreign currency items are translated to NOK at the exchange rate on the balance sheet date. Non-monetary items that are measured at historical cost in a foreign currency are translated to NOK using the exchange rate on the transaction date. Non-monetary items that are measured at fair value in a foreign currency are translated to NOK using the exchange rate on the measurement date. Exchange rate fluctuations are posted to the profit and loss account as they arise under other financial items.

Revenues

Revenues from the sale of goods are recognised in the profit and loss account once delivery have taken place. Service revenues are recognized over the period the services are performed.

Tax

The tax charge in the profit and loss account consists of tax payable for the period and the change in deferred tax. Deferred tax is calculated at the tax rate at 22 % on the basis of tax-reducing and tax-increasing temporary differences that exist between accounting and tax values, and the tax loss carried forward at the end of the accounting year. Tax-increasing and tax-reducing temporary differences that reverse or may reverse in the same period are set off and entered net. The net deferred tax receivable is entered on the balance sheet to the extent that it is likely that it can be utilised.

Classification and valuation of fixed assets

Fixed assets consist of assets intended for long-term ownership and use. Fixed assets are valued at acquisition cost less depreciation and write-downs.

Plant and equipment is capitalised and appreciated over the economic lifetime of the asset. Significant items of plant and equipment that consist of several material components with different lifetimes are broken down in order to establish different depreciation periods for the different components. Direct maintenance of plant and equipment is expensed on an ongoing basis under operating costs, while additions or improvements are added to the asset's cost price and depreciated in line with the asset. Plant and equipment is written down to the recoverable amount in the event of a fall in value that is not expected to be temporary. The recoverable amount is the higher of the net sales value and the value in use. Value in use is the present value of future cash flows related to the asset. The write-down is reversed when the basis for the write-down is no longer present.

Classification and valuation of current assets and current liabilities

Current assets and short-term liabilities consist normally of items that fall due for payment within one year of the balance sheet date, as well as items related to the stock cycle. Current assets are valued at the lower of acquisition cost and fair value. Short-term liabilities are entered on the balance sheet at the nominal amount at the time of the transaction.



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Inventory

Inventory consists of goods for resale and is valued at the lower of acquisition cost and net sale value. Sale value is the estimated sale price in ordinary operations after deduction of estimated necessary expenses for completing the sale. Acquisition cost includes expenses incurred in acquiring goods and costs necessary to bring the goods to the present position and are attributed using the FIFO principle.

Receivables

Receivables from customers and other receivables are entered at par value after deducting a provision for expected losses. The provision for losses is made on the basis of an individual assessment of the respective receivables. In addition an unspecified provision is made to cover expected losses on claims in respect of customer receivables.

Pension

The entity has a collective pension insurance that covers all employees. The scheme is a contribution scheme. The years pension premium, adjusted for any payment or deductions to the deposit fund, is recognized as pension cost. The entities pension scheme satisfies the requirements of the Act on Mandatory Occupational Pensions.

Cash flow statement

The cash flow statement has been prepared using the indirect method.

Cash and cash equivalents consist of cash and bank deposits.

Intercompany cash flows in 2021, which were classified as cash flows from investments and financing, are reclassified due to the nature of these cash flows to cash flow from operational activities. This reclassification has no effect on equity.



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Note 2 Sales revenue

By business area		2022	2021
ImmunoDiagnostics	Product	2 277 981	2 222 981
ImmunoDiagnostics	Consumables	62 371 204	66 007 511
ImmunoDiagnostics	Service	1 665 068	1 969 287
Microbiology	Product	326 540	537 086
Microbiology	Consumables	29 623 866	29 195 017
Microbiology	Service	624 700	103 568
Clinical Diagnostics	Product	260 068	8 068
Clinical Diagnostics	Consumables	24 814 821	29 075 522
Clinical Diagnostics	Service	1 426 332	1 421 834
Chromatography and Mass Spec Businesses	Consumables	725	10 125
Other		3 747	0
Total		123 395 052	130 550 999

Geographic breakdown	2022	2021
Nordics	123 395 052	130 550 999

Note 3 Intercompany transactions

Main intercompany transactions in 2022 were as listed below.

Company name	Transaction	Relationship	Amount
B R A H M S GmbH	Intercompany purchase/ Cogs	Sister	16 981 089
Cezanne S A S	Intercompany purchase/ Cogs	Sister	83 097
Microgenics BV & Co KG	Intercompany purchase/ Cogs	Sister	5 782 223
Oxoid Deutschland GmbH	Intercompany purchase/ Cogs	Sister	10 476 448
Oxoid Limited	Intercompany purchase/ Cogs	Parent	3 742 114
Phadia AB	Intercompany purchase/ Cogs	Sister	60 485 365
Thermo Fisher Diagnostics AB	Intercompany purchase/ Cogs	Sister	30 523
Thermo Fisher Diagnostics Aps	Intercompany purchase/ Cogs	Sister	20 654
Thermo Fisher Scientific Oy	Intercompany purchase/ Cogs	Sister	239 949
Trek Diagnostic Systems Limited	Intercompany purchase/ Cogs	Sister	981 074
Total			98 822 536

Other intercompany transactions are sale of goods, rental, management services, interests on intercompany loan and other financial costs.

Note 4 Inventory

	2022	2021
Finished goods for resale	551 601	760 788
Total net inventory	551 601	760 788

Total cost of goods in the period	98 571 109	99 077 323
Book value of inventory provided as security	0	0



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Note 5 Salary costs and benefits, remuneration to the chief executive officer, board and auditor

Salary costs	2022	2021
Salaries	11 816 388	12 168 896
Employment tax	1 816 034	1 713 218
Pension costs	716 659	181 039
Other benefits	93 771	5 857
Total	14 442 853	14 069 010

In 2022 the company had 15 full time equivalents (13 in 2021).

Pension

The company is liable to maintain an occupational pension scheme under the Mandatory Occupational Pensions Act. The company's pension schemes satisfy the requirements of this Act.

Remuneration to leading personnel	Chief executive officer	Board
Salaries	1 334 652	0
Other remuneration	155 050	0
Total	1 489 702	0

No loan/guarantees have been granted to chairman of the board or other related parties.

Auditor

Audit fees expensed for 2022 amount to NOK 106 000.

In addition there is a fee for preparation of financial statements of NOK 85 000.

Note 6 Non-current assets

	Goodwill	Machinery and equipment	Total
Acquisition cost as at 01.01.2022	12 823 464	11 892 737	24 716 201
Addition of purchased fixed assets	0	0	0
Disposals of fixed assets	0	0	0
Acquisition cost 31.12.2022	12 823 464	11 892 737	24 716 200
Depreciation and write-downs as at 01.01.2022	-12 182 291	-10 384 959	-22 567 250
Ordinary depreciation for the year	-641 173	-347 382	-988 554
Reversal of depreciation due to disposal of fixed assets	0	0	0
Depreciation and write-downs as at 31.12.2022	-12 823 464	-10 732 341	-23 555 804
Book value 01.01.2022	641 173	1 507 778	2 148 951
Additions in the year	0	0	0
Disposals in the year	0	0	0
Depreciation and write-downs for the year	-641 173	-347 382	-988 554
Book value 31.12.2022	0	1 160 397	1 160 397
Useful life	5 years	6 years	
Depreciation plan	Linear	Linear	



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Note 7 Tax

Temporary differences	2022	2021
Fixed assets	-4 522 045	-4 974 652
Receivables	-29 031	0
Accruals and provision	-550 047	-475 302
Inventory	-256 313	-98 250
Total temporary differences before tax losses to carry forward	-5 357 436	-5 548 204
Tax loss to carry forward	-67 051 450	-67 144 382
Temporary differences from merger with FEI Trondheim AS	0	67 418 552
Tax base - Deferred tax liability (asset)	-72 408 886	-5 274 034
Deferred tax liability (asset) 22%/22%	-15 929 955	-1 160 287

Calculation of taxable income

Pretax income	-501 734	3 994 556
Permanent differences	785 434	115 928
Temporary differences	-190 769	1 218 067
Taxable income before loss carry forward	92 932	5 328 551
Loss carry forward - utilisation	-92 932	0
Taxable income	0	5 328 551

Specification of tax expense

Tax payable	0	1 172 281
Change in deferred tax asset	-14 769 667	-267 975
Effect of deferred tax asset recognised as part of merger with FEI Trondheim AS pr. 01.01.2022	14 832 081	0
Total tax expense in profit and loss account	62 414	904 306

Tax payable in balance sheet

Tax payable	0	1 172 281
Tax payable in balance sheet	0	1 172 281

The following temporary differences of FEI Trondheim AS pr. 01.01.2022 have been incorporated in opening balance of tax positions:

Fixed assets	-265 109
Accruals and provision	-9 060
Tax loss to carry forward	-67 144 382
Total	-67 418 552



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBB01C3680

Note 8 Intercompany balances with group companies and associates

Receivables from companies in the same group

	2022	2021
Fisher Scientific A/S	42 331	19 929
Thermo Electron AB	94 458	0
FEI Electron Optics BV	227 391	0
Thermo Fisher Scientific Brno S.r.o.	545 374	0
Fisher Scientific Company	45 253	0
Brahms Gmbh	764 615	182 306
FEI Europe BV	222 157	6 579
Phadia AB	4 161 754	6 480 230
Intercompany cash pool - receivables	6 808 508	15 505 770
Total	12 911 841	22 194 814

Liabilities to companies in the same group

	2022	2021
Thermo Fisher Scientific Inc	91 168	7 991
Thermo Fisher Scientific Oy	0	54 404
Thermo Fisher Diagnostics ApS	68 338	68 223
Thermo Fisher Diagnostics BV	60 490	0
Thermo Fisher Diagnostics GmbH	261 568	0
Thermo Electron (Management Services) Ltd	1 028 404	283 444
Brahms Gmbh	0	0
Cezanne SAS	0	36 064
Oxoid Limited	3 004 861	1 453 082
Microgenics BV and Co KG	0	317 468
Oxoid Deutschland GmbH	8 127 216	2 595 555
Trek Diagnostic Systems Ltd	179 682	34 378
Remel Inc	0	0
Life Technologies Ltd	374 437	163 760
Life Technologies AS	0	208 868
One Lambda Inc.	0	0
Phadia AB	0	0
Intercompany cash pool - debt	0	17 377 563
Total	13 196 163	22 600 800

Thermo Fisher Diagnostics AS has not provided any guarantees for the other concern companies.



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Note 9 Receivables and liabilities

	2022	2021
Assets with maturity later than one year	0	0
Long-term liabilities with maturity later than 5 years	0	0

None of the company's liabilities are secured by the company's assets.
The company has no guarantee obligations.

Note 10 Restricted funds

Restricted funds	2022	2021
Bank deposit for employees withholding tax	3 722 298	3 660 850

Note 11 Share capital and shareholder information

Share capital	Number	Par value	Capitalised
Ordinary shares	1 000	100	100 000

All shares carry the same rights in the company.

Thermo Fisher Diagnostics AS is wholly owned by Oxoid International Ltd.
The chief executive officer and board members do not own any shares in the company.

The ultimate parent company is Thermo Fisher Scientific Inc. which is based in Waltham, MA USA.
Consolidated accounts of Thermo Fisher Scientific Inc., which include Thermo Fisher Diagnostics AS can be received on 168 Third Avenue, Waltham, MA USA 02451.

Note 12 Equity

	Share capital	Share premium reserve	Retained earnings	Total equity capital
As at 31.12.2021	100 000	200 000	7 507 543	7 807 543
Effect of merger with FEI Trondheim AS with effect on 01.01.2022			15 096 006	15 096 006
As at 01.01.2022	100 000	200 000	22 603 549	22 903 549
Result for the year			-564 148	-564 148
As at 31.12.2022	100 000	200 000	22 039 401	22 339 401



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Note 13 Merger

In May 2022, Thermo Fisher Diagnostics AS purchased 100% shares in FEI Trondheim AS .
The seller of the shares in FEI Trondheim AS was FEI Norway Holdings AS which is a company in the Thermo group. The value of the transaction was priced in accordance with the booked equity of FEI Trondheim AS.

Later in 2022, in order to achieve a more simplified legal structure in Thermo Fisher Scientific group, there was completed merger between the parent company Thermo Fisher Diagnostics AS, the acquiring company, and its wholly owned subsidiary FEI Trondheim AS, the transferor company. The merge was finalised on 21.09.2022 with implementation effect from 01.01.2022. FEI Trondheim AS was dissolved on 21.09.2022.

The merge was carried out according to the simplified parent-subsiary merger rules of the Companies Act § 13-23. In accordance with the Companies Act § 13-23, no consideration shall be granted for the merger.

In terms of accounting, the merger was carried out in accordance with the rules on company continuity. Assets, rights and liabilities in the merged company, FEI Trondheim AS, are transferred to the acquiring company, Thermo Fisher Diagnostics AS, with the values used in the company financial statements.

In terms of taxation, the merger is implemented with full tax continuity.

The cash flow statement presents the Net acquired cash through acquisition using the continuity principle and values from FEI Trondheim AS as per 01.01.2021. All other adjustments to intercompany accounts related to the transaction are presented as adjustments in the change in other timing differences in the operating cash flow.

The acquisition was settled using the group cash pool.



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Board of Directors Report for the year ended 31 December 2022

The directors of Thermo Fisher Diagnostics AS (the Company) present their annual report together with the audited annual accounts of the Company for the financial period ended December 31, 2022.

Thermo Fisher Diagnostics AS was incorporated in 2004 and is a wholly owned subsidiary of Oxoid International Ltd. Based in Altrincham, England. The ultimate parent is Thermo Fisher Scientific Inc.

The Business address for Thermo Fisher Diagnostics AS is Ullernchausseen 52 0379, Oslo, Norway

Principal activities

Thermo Fisher Diagnostics AS is part of the Specialty Diagnostics Group of Thermo Fisher Scientific and operates in three divisions:

- ImmunoDiagnostics division (IDD) develops, produces and markets innovative blood test systems ensuring correct diagnoses of blood samples and monitoring of allergy, asthma and autoimmune diseases.
- Microbiology division (MBD) sells and distributes Microbiology products for the clinical market (e.g. prepared culture media, rapid diagnostics test), pharmaceutical market (e.g. sterility testing, quality control) and food market (rapid culture methods, identification tests).
- Clinical diagnostics division (CDD) sells and distributes clinical diagnostic products and is product leader in drugs of abuse testing, sepsis diagnosis, quality control materials like molecular controls and laboratory automation.

Research and Development activities

The company is not active in Research and Development and is not planning on incurring any significant Research and Development costs in the future.

Objectives and policies for risk management

It is Thermo Fisher Diagnostics AS' objective to assess risk on a regular basis. Activities that need to be performed from a risk perspective are laid out in corporate policies.

Financial risk management

Currently Thermo Fisher Diagnostics AS has assessed the currency risk and has determined not to hedge these currency risks. These risks mainly result from positions in currencies outside the Euro zone. The Board of Directors has assessed that limited risk exists since the valuation of securities relates only to cash at bank and in hand. The Board of Directors has assessed the interest rate risk and has determined not to enter financial derivatives. To manage credit risk customers are assessed for their credit worthiness.

Competitive Risks

The markets for our products and services are very competitive and price sensitive. Our competitors have significant financial, operational, sales and marketing resources, and experience in research and development. Our competitors could develop new technologies that compete with our products and services or even render our products and services obsolete. If a competitor develops superior technology or cost-effective alternatives to our products and services, our business could be seriously harmed. The markets for some of our products are also subject to specific competitive risks. These



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

markets are highly price competitive. Our competitors have competed in the past by lowering prices on certain products. If they do so again, we may be forced to respond by lowering our prices and thereby reducing our revenues and profits. Failure to anticipate and respond to price competition may hurt our competitive position. Response would be Price Benchmarking competition and Strengthening Brands.

Economic Risks

The global economy still has economic challenges. In the event of worsening economic conditions in the businesses or geographic areas in which we sell our products, and/or services, demand for our products, and/or services, could be reduced and result in a decrease in sales volume that could have a negative impact on our results of operations. Global credit and capital markets continue to experience volatility and disruption.

Funding Risks

Our customers include researchers at pharmaceutical and biotechnology companies, academic institutions, government laboratories and private foundations. Fluctuations in the research and development budgets of these researchers and their organisations could have a significant effect on the demand for our products. Budgets may fluctuate due to mergers of pharmaceutical and biotechnology companies, site consolidations or relocations to other parts of the globe, spending priorities, general economic conditions and institutional and governmental budgetary policies.

Response such as Analysis of economic developments; Diversifying customer segment portfolio.

Financial position

The company has implemented policies that require appropriate credit checks on potential customers before a sale is made. The amount of exposure to any individual counterparty is subject to a limit, which is continually reviewed by the senior management team.

Financial reporting Revenue Recognition

Risks of inappropriate revenue recognition around the financial year end. Response to the risk is Revenue Recognition - Sales orders are reviewed to ensure 1) Persuasive evidence of an arrangement exists 2) Delivery of products occurred or services rendered 3) The selling price is fixed or determinable 4) Collectability is reasonably assured

Laws and regulations

A changing legislative and regulatory environment increases the cost of doing business, tax levels and the complexity of our operations. Response - Knowledge and awareness of regulations; Monitoring, review and reporting of changes; Operational procedure and guidance

Financing and Investments

The company is mainly financed through short-term cash.

Development in profit and loss, balance sheet and cash flows

The net loss of the Company for the financial year was NOK 564,148 (2021: NOK 3,090,249 profit). The company paid dividends of NOK nil during the year (2020: NOK nil) and received dividends of NOK nil (2020: NOK nil). The directors recommend the net profit be allocated to retained earnings. Total assets



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

as at December 31, 2022 total NOK 47,274,955 (2021: NOK 42,618,469). The company has prospects of positive earnings going forward and given the positive equity and access to group funding the Company prepares the financial statements based on the going concern assumption.

Net cash out flow from operating activities was NOK 2,176,222 for 2022, Loss before income taxes was NOK 501,734. Cash flow from investments through acquisition was NOK 2,237,670.

Cash at year end was NOK 3,722,298.

Number of employees

The average number of employees in 2022 amounted to 15 (2021: 13). At the year end, the actual number of employees was 14 (2021: 12)

Absence due to illness was recorded in operations as 2.7%, Illnesses supported with a doctor's note totaled 74 days (555 hours). Illnesses not supported with a doctor's note totaled 17 days (135 hours).

Directors' indemnification

The ultimate parent company, Thermo Fisher Scientific Inc. maintains liability insurance for its Directors and Officers. These indemnities are uncapped in amount (subject to certain exceptions) in relation to losses and liabilities which they may incur to third parties in the course of acting as a Director or Officer of the Company. The indemnity will continue for the benefit of Directors and Officers on an ongoing basis.

Working environment

Wages are adjusted to the position's demand for responsibility, skills and market wages. The Company provides remuneration based on the performance and results of the individual employee.

The operation emphasizes being an attractive place to work and attracts the best employees. Thermo Fisher Diagnostics AS is engaged in developing and utilizing diversity in the organization both as regards sex, age, skills, and cultural background.

Thermo Fisher Diagnostics AS continually works with monitoring and following up on health, environment, safety, and job satisfaction. Necessary control measures are documented, and the results evaluated. There have been no accidents or injuries in the workplace. The working environment is good.

Environmental impact

Our mission is to enable our customers to make the world healthier, cleaner and safer. One way that we fulfil our Mission is by being a socially responsible community partner. Our giving strategy includes educational programs, colleague donations and volunteering.



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Our signature STEM education programs connect students and colleagues through hands on and team based activities that highlight our technologies, make connections to careers in STEM and demonstrate how our company impacts the world.

To promote the generous spirit of our colleagues, our Charitable Giving Program provides a platform that allows them to contribute to causes that they feel passionately about. Through the program, employees can make direct donations to a charity of their choice, create a fundraiser - gathering greater support for a cause, or contribute to support a disaster relief campaign. Through our Employee Matching Gift program, we help employees make an even bigger impact by matching their contribution to eligible charities by 50%.

We feel it is important to support our community, throughout the year we encourage employees to take part in volunteering and charity events where our employees, together with our charity partners, take part in hands on volunteering.

The company is a part of Thermo Fisher Scientific Inc.'s global strategy to reduce our carbon footprint by 30% by 2030. As part of this global initiative, we are committed to reviewing and reducing greenhouse gas emissions.

The impact on the environment is insignificant for Thermo Fisher Diagnostics AS.

Merger

Following an internal review of the Thermo Fisher Scientific Inc.'s legal structure, it was determined that the legal entity FEI Trondheim AS was to be merged with Thermo Fisher Diagnostics AS effective 21 September 2022 with all assets and liabilities being merged at book value. This merger would reduce costs for the group as the reduction in legal entities would result in lower administrative and compliance costs, improve risk management with better legal entity governance and control and support internal business optimisations.

The Transparency Act

The Transparency Act entered into force on 1 July 2022. The purpose of the act is to promote businesses' respect for human rights and decent working conditions, as well as ensure the public's access to information. Thermo Fisher Diagnostics AS is underway with this work, but this is an area that will be further developed and followed up continuously. Refer to the "2022 Corporate Social Responsibility Report" that can be found on the website of Thermo Fisher Scientific Inc.

Outlook

The company believes its long term prospects remain excellent given the attractive markets served, its industry leading position and proven growth strategy. There is no uncertainty about going concern.



DocuSign Envelope ID: 8DD95453-45F3-481F-B827-4CBBD01C3680

Subsequent events

There are no subsequent events to disclose.

DocuSigned by:
Petrus Thomas Adrianus van der Zande
B44A9F4F4B664ED

Petrus Van Der Zande
Chair of the Board of Directors

DocuSigned by:
Anne Omholt
06093D1C6C534D5

Anne Omholt
Member/General Manager

DocuSigned by:
Sara Maria Carrella
87B7F8E3A4794AD

Sara Maria Carrella
Member



Skatteetaten

Vår dato 20.05.2019	Din/Deres dato 20.03.2019	Saksbehandler Henning Stokke
800 80 000 Skatteetaten.no	Din/Deres referanse Jørgen Viktil	Telefon 800 80 000
Org.nr 974761076	Vår referanse 2019/5560226	Postadresse Postboks 9200 Grønland 0134 OSLO

THERMO FISHER SCIENTIFIC NORWAY HOLDINGS AS
c/o Life Technologies Postboks 114 Smestad
0309 OSLO

Tillatelse til å utarbeide årsberetning og årsregnskap på engelsk språk for Thermo Fisher Diagnostics AS, org.nr. 986 400 990

Vi viser til deres brev av 20. mars 2019 der det søkes om dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk for Thermo Fisher Diagnostics AS.

Skattedirektoratet gir på bakgrunn av en konkret helhetsvurdering Thermo Fisher Diagnostics AS dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk, jf. regnskapsloven § 3-4 tredje ledd. Dispensasjonen gjelder så lenge opplysningene som vedtaket baserer seg på ikke endres vesentlig.

Kopi av dette brevet må sendes Regnskapsregisteret i Brønnøysund sammen med årsregnskapet. Det påligger den regnskapspliktige å dokumentere ved dette brev at tillatelsen er gitt.

Bakgrunn

Fra søknaden gjengis:

Søknaden omfatter det norske selskapet Thermo Fisher Diagnostics AS (986400990). Selskapets virksomhet består av salg av medisinsk utstyr og materiell til farmasøytiske selskaper, sykehus og andre biotekniske selskaper. Thermo Fisher Diagnostics AS er del av Thermo Fisher Scientific Inc. som er konsernspiss og børsnotert i USA. Selskapet har 14 ansatte.

Thermo Fisher Diagnostics AS ble stiftet i 9. desember 2003. Selskapet kontrolleres av eeneier Oxoid International Ltd. Administrasjonen av selskapet gjøres i betydelig grad fra Glasgow UK. Selskapet vil utarbeide årsregnskap på engelsk og konsernets rapportennngsspråk er engelsk. Selskapets nåværende og fremtidige aksjonærer er profesjonelle investorer som opererer i et engelskspråklig forretningsmiljø, og som støtter at selskapet utarbeider årsregnskapet på engelsk. Selskapet vil utarbeide selskapsdokumenter på engelsk så langt dette er tillatt. Språket som benyttes i formell kommunikasjon er i hovedsak engelsk. Dette forutsettes ved nyansettelser i Thermo Fisher Scientific inc. konsernet.



Konsernets eiere, styremedlemmer og eksterne interessenter ønsker informasjon på engelsk. En rekke av selskapets interessenter behersker i begrenset grad norsk, herunder internasjonalt ansatte og internasjonale kreditorer, og vil således måtte oversette årsregnskapet til engelsk for å kunne ta stilling til dette.

Thermo Fisher Diagnostics har inngått vesentlige konserninterne avtaler med internasjonale selskaper i gruppen. Konsernets kunder vil i stor grad være internasjonale kunder. Selskapets eksterne kreditorer utgjør i hovedsak profesjonelle aktører som benytter engelsk som forretningspråk. Dette omfatter leverandører av finansielle tjenester samt leveranser av varer og tjenester til utvikling og drift av konsernets salgsvirksomhet av medisinsk utstyr.

For selskapet er det både tids- og kostnadskrevende å oversette regnskapet fra engelsk til norsk, og det fremstår derfor som en unødvendig byrde og konkurranseulempe å utarbeide årsregnskapet på norsk. Brukerne av regnskapsinformasjonen vil ikke bli negativt påvirket av at regnskapene blir avgitt kun på engelsk.

Skattedirektoratets vurdering

Etter regnskapsloven § 3-4 tredje ledd skal "årsregnskapet og årsberetningen ... være på norsk. Departementet kan ved ... enkeltvedtak bestemme at årsregnskapet og/eller årsberetningen kan være på et annet språk."

I Ot. prp. nr. 42 (1997-1998) Om lov om årsregnskap m.v., er det uttalt følgende om regnskapslovens formål, jf. pkt. 1.1:

"Regjeringen har som siktemål at regnskapsloven skal bidra til informative regnskaper for ulike grupper av regnskapsbrukere. Regnskapsbrukerne er dels investorer og kreditorer som tilfører kapital til foretakene, og dels andre grupper som har interesse av å vite hvordan foretaket drives, f.eks. de ansatte og lokalsamfunnet. Informasjonen til kapitalmarkedet skal gi grunnlag for riktig prising av finansielle objekter. Riktig prisdannelse på aksjer er en forutsetning for at ressursbruken i samfunnsøkonomien skal bli best mulig. Gode regnskaper vil også gjøre det vanskeligere for markedsdeltakere å ta ut spekulasjonsgevinster med basis i skjevt fordelt informasjon."

Det fremgår således at et av hovedformålene med regnskapsloven er å bidra til "informative regnskaper for ulike grupper av regnskapsbrukere". Regnskapsbrukere vil omfatte, jf. uttalelsen i proposisjonen, blant andre investorer, kreditorer, ansatte og lokalsamfunnet.

Det er etter Skattedirektoratets vurdering derfor avgjørende ved vurdering av om dispensasjon fra kravet til å utarbeide årsregnskap og/eller årsberetning på norsk kan gis, at det ikke foreligger mulige brukere av regnskapsinformasjon som blir vesentlig berørt negativt ved en eventuell dispensasjon.

Som nevnt ovenfor er det er særlig hensynet til brukerne av regnskapsinformasjon som skal vurderes ved en dispensasjonssøknad. I denne vurderingen har Skattedirektoratet lagt vekt på at selskapet er heleid av



et utenlandsk selskap. I tillegg opererer selskapet i en internasjonal bransje, og arbeidsspråket er engelsk. Videre er det vektlagt at alle sentrale aktører og samarbeidspartnere innen denne bransjen behersker og benytter engelsk.

Vennligst oppgi vår referanse ved henvendelser i saken.

Med hilsen

Inger Helene Iversen
seniorrådgiver
Juridisk avdeling
Skattedirektoratet

Henning Stokke

Dokumentet er elektronisk godkjent og har derfor ikke håndskrevne signaturer.



To the General Meeting of Thermo Fisher Diagnostics AS

Independent Auditor's Report

Opinion

We have audited the financial statements of Thermo Fisher Diagnostics AS (the Company), which comprise the balance sheet as at 31 December 2022, the income statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion

- the financial statements comply with applicable statutory requirements, and
- the financial statements give a true and fair view of the financial position of the Company as at 31 December 2022, and its financial performance for the year then ended in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company as required by laws and regulations and the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Matters

The Company's financial statements have been submitted after the expiry of the statutory time limit for preparation of financial statements.

Other Information

The Board of Directors and the Managing Director (management) are responsible for the information in the Board of Directors' report. The other information comprises information in the annual report, but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the information in the Board of Directors' report.

In connection with our audit of the financial statements, our responsibility is to read the Board of Directors' report. The purpose is to consider if there is material inconsistency between the Board of Directors' report and the financial statements or our knowledge obtained in the audit, or whether the Board of Directors' report otherwise appears to be materially misstated. We are required to report if there is a material misstatement in the Board of Directors' report. We have nothing to report in this regard.

PricewaterhouseCoopers AS, Dronning Eufemias gate 71, Postboks 748 Sentrum, NO-0106 Oslo
T: 02316, org. no.: 987 009 713 MVA, www.pwc.no
Statsautoriserte revisorer, medlemmer av Den norske Revisorforening og autorisert regnskapsførerselskap



Based on our knowledge obtained in the audit, it is our opinion that the Board of Directors' report

- is consistent with the financial statements and
- contains the information required by applicable legal requirements.

Responsibilities of the Board of Directors and the Managing Director for the Financial Statements

The Board of Directors and the Managing Director (management) are responsible for the preparation of financial statements that give a true and fair view in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern. The financial statements use the going concern basis of accounting insofar as it is not likely that the enterprise will cease operations.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

For further description of Auditor's Responsibilities for the Audit of the Financial Statements reference is made to: <https://revisorforeningen.no/revisjonsberetninger>

Oslo, 5 July 2023

PricewaterhouseCoopers AS

Sjur Holseter

State Authorised Public Accountant